SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

News

For SELLAS Life Sciences Group, Inc., read summarized stories built from several publishers and recent headlines with links to the original coverage.

Products & Launches

SELLAS Says Phase 3 REGAL Trial of GPS Cancer Vaccine Meets Primary Endpoint

SELLAS Life Sciences Group said its pivotal Phase 3 REGAL study of galinpepimut-S (GPS), an investigational immunotherapeutic cancer vaccine, met its primary endpoint in patients with acute myeloid leukemia. According to the company, GPS produced a statistically significant and clinically relevant 41% reduction in the risk of death, with median overall survival that was longer than that seen with the best available treatment.

SELLAS said it intends to meet with the U.S. Food and Drug Administration while it continues preparations to submit a biologics license application (BLA) for GPS. The company discussed the top-line results on a webcast held on Nov 17, 2026, led by founder, president and CEO Angelos Stergiou.

The shares jumped to a 52-week high in the session following the announcement, on volume of 57.567 million against an average of 6.897 million, according to market data cited in one report. SELLAS remains a pre-revenue company, recording revenue of 0.00 USD and a net loss of 26.9 million USD, or diluted EPS of -0.25 USD, in fiscal 2025.

More headlines

Recent coverage that has not been summarized. Links open the publisher's site.